A selective estrogen receptor α agonist ameliorates hepatic steatosis in the male aromatase knockout mouse

Journal of Endocrinology

Volumn 210, Issue 3, 2011, Pages 323-334

  Chow, Jenny D Y ^a,b   Jones, Margaret E E ^a,b   Prelle, Katja ^c   Simpson, Evan R ^a,b   Boon, Wah Chin ^a,b,d  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c BAYER PHARMA AG   (Germany)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3,17 DIHYDROXY 19 NOR 17ALPHA PREGNA 1,3,5(10) TRIENE 21,16ALPHA LACTONE; 8 VINYLESTRA 1,3,5(10) TRIENE 3,1,7BETA DIOL; ACYL COENZYME A DESATURASE; ANDROGEN RECEPTOR; AROMATASE; BETA TUBULIN; CARNITINE PALMITOYLTRANSFERASE I; ESTRADIOL; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA AGONIST; ESTROGEN RECEPTOR BETA; FATTY ACID SYNTHASE; HORMONE RECEPTOR AFFECTING AGENT; STEAROYL COENZYME A DESATURASE 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARCUATE NUCLEUS; ARTICLE; CONTROLLED STUDY; DRUG SELECTIVITY; FASN GENE; FATTY ACID OXIDATION; FATTY LIVER; GENE; GENE EXPRESSION; HOMEOSTASIS; KNOCKOUT MOUSE; LIVER FUNCTION; LIVER HISTOLOGY; MALE; MITOCHONDRION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WILD TYPE;

ANIMALS; AROMATASE; BASE SEQUENCE; DISEASE MODELS, ANIMAL; DNA PRIMERS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FATTY ACIDS; FATTY LIVER; LIVER; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; RNA; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION; TRIGLYCERIDES;

EID: 80052762932     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-10-0462     Document Type: Article

References (58)

1. Adams LA & Angulo P 2006 Treatment of non-alcoholic fatty liver disease. Postgraduate Medical Journal 82 315-322.
2. Angulo P 2002 Nonalcoholic fatty liver disease. New England Journal of Medicine 346 1221-1231.
3. Angulo P, Keach JC, Batts KP & Lindor KD 1999 Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Hepatology 30 1356-1362.
4. Biddinger SB, Miyazaki M, Boucher J, Ntambi JM & Kahn CR 2006 Leptin suppresses stearoyl-CoA desaturase 1 by mechanisms independent of insulin and sterol regulatory element-binding protein-1c. Diabetes 55 2032-2041.
5. Boon WC, Diepstraten J, van der Burg J, Jones ME, Simpson ER & van den Buuse M 2005 Hippocampal NMDA receptor subunit expression and watermaze learning in estrogen deficient female mice. Brain Research. Molecular Brain Research 140 127-132.
6. Bradbury MW 2006 Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: possible role in steatosis. American Journal of Physiology. Gastrointestinal and Liver Physiology 290 G194-G198.
7. Brasaemle D, Barber T, Wolins N, Serrero G, Blanchette-Mackie E & Londos C 1997 Adipose differentiation-related protein is an ubiquitously expressed lipid storage droplet-associated protein. Journal of Lipid Research 38 2249-2263.
8. Brown MS & Goldstein JL 1997 The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89 331-340.
9. Clark JM, Brancati FL & Diehl AM 2003 The prevalence and etiology of elevated aminotransferase levels in the United States. American Journal of Gastroenterology 98 960-967.
10. Cole LK, Jacobs RL & Vance DE 2010 Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis. Hepatology 52 1258-1265.
11. Couse JF, Lindzey J, Grandien K, Gustafsson J-A & Korach KS 1997 Tissue distribution and quantitative analysis of estrogen receptor-α (ERα) and estrogen receptor-β (ERβ) messenger ribonucleic acid in the wild-type and ERa-knockout mouse. Endocrinology 138 4613-4621.
12. Della Torre S, Biserni A, Rando G, Monteleone G, Ciana P, Komm B & Maggi A 2011 The conundrum of estrogen receptor oscillatory activity in the search for an appropriate hormone replacement therapy. Endocrinology 152 2256-2265.
13. Dixon JB, Bhathal PS & O'Brien PE 2001 Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121 91-100.
14. Edwards PA, Tabor D, Kast HR & Venkateswaran A 2000 Regulation of gene expression by SREBP and SCAP. Biochimica et Biophysica Acta 1529 103-113.
15. Fisher CR, Graves KH, Parlow AF & Simpson ER 1998 Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. PNAS 95 6965-6970.
16. Gruber CJ, Tschugguel W, Schneeberger C & Huber JC 2002 Production and actions of estrogens. New England Journal of Medicine 346 340-352.
17. Hewitt KN, Pratis K, Jones ME & Simpson ER 2004 Estrogen replacement reverses the hepatic steatosis phenotype in the male aromatase knockout mouse. Endocrinology 145 1842-1848.
18. Hill RA, Pompolo S, Jones ME, Simpson ER & Boon WC 2004 Estrogen deficiency leads to apoptosis in dopaminergic neurons in the medial preoptic area and arcuate nucleus of male mice. Molecular and Cellular Neurosciences 27 466-476.
19. Hill RA, Chow J, Fritzemeier K, Simpson ER & Boon WC 2007a Fas/FasLmediated apoptosis in the arcuate nucleus and medial preoptic area of male ArKO mice is ameliorated by selective estrogen receptor alpha and estrogen receptor beta agonist treatment, respectively. Molecular and Cellular Neurosciences 36 146-157.
20. Hill RA, McInnes KJ, Gong ECH, Jones MEE, Simpson ER & Boon WC 2007b Estrogen deficient male mice develop compulsive behavior. Biological Psychiatry 61 359-366.
21. Hillisch A, Peters O, Kosemund D, Müller G, Walter A, Schneider B, Reddersen G, Elger W & Fritzemeier KH 2004 Dissecting physiological roles of estrogen receptor alpha and beta with potent selective ligands from structure-based design. Molecular Endocrinology 18 1599-1609.
22. Horton JD, Goldstein JL & Brown MS 2002 SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. Journal of Clinical Investigation 109 1125-1131.
23. James OF & Day CP 1998 Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. Journal of Hepatology 29 495-501.
24. Jones ME, Thorburn AW, Britt KL, Hewitt KN, Wreford NG, Proietto J, Oz OK, Leury BJ, Robertson KM, Yao S et al. 2000 Aromatasedeficient (ArKO) mice have a phenotype of increased adiposity. PNAS 97 12735-12740.
25. Jones ME, Thorburn AW, Britt KL, Hewitt KN, Misso ML, Wreford NG, Proietto J, Oz OK, Leury BJ, Robertson KM et al. 2001 Aromatasedeficient (ArKO) mice accumulate excess adipose tissue. Journal of Steroid Biochemistry and Molecular Biology 79 3-9.
26. Lundholm L, Movérare S, Steffensen KR, Nilsson M, Otsuki M, Ohlsson C, Gustafsson JA & Dahlman-Wright K 2004 Gene expression profiling identifies liver X receptor alpha as an estrogen-regulated gene in mouse adipose tissue. Journal of Molecular Endocrinology 32 879-892.
27. Maffei L, Murata Y, Rochira V, Tubert G, Aranda C, Vazquez M, Clyne CD, Davis S, Simpson ER & Carani C 2004 Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. Journal of Clinical Endocrinology and Metabolism 89 61-70.
28. Matthews J & Gustafsson JA 2003 Estrogen signaling: a subtle balance between ER alpha and ER beta. Molecular Interventions 3 281-292.
29. McGarry JD, Leatherman GF & Foster DW 1978 Carnitine palmitoyltransferase I. The site of inhibition of hepatic fatty acid oxidation by malonyl-CoA. Journal of Biological Chemistry 253 4128-4136.
30. McInnes K, Corbould JA, Simpson ER & Jones ME 2006 Regulation of adenosine 5′,monophosphate-activated protein kinase and lipogenesis by androgens contributes to visceral obesity in an estrogen-deficient state. Endocrinology 147 5907-5913.
31. Misso ML, Murata Y, Boon WC, Jones ME, Britt KL & Simpson ER 2003 Cellular and molecular characterization of the adipose phenotype of the aromatase-deficient mouse. Endocrinology 144 1474-1480.
32. Mitra SW, Hoskin E, Yudkovitz J, Pear L,Wilkinson HA, Hayashi S, Pfaff DW, Ogawa S, Rohrer SP, Schaeffer JM et al. 2003 Immunolocalization of estrogen receptor beta in the mouse brain: comparison with estrogen receptor alpha. Endocrinology 144 2055-2067.
33. Motomura W, Inoue M, Ohtake T, Takahashi N, Nagamine M, Tanno S, Kohgo Y & Okumura T 2006 Up-regulation of ADRP in fatty liver in human and liver steatosis in mice fed with high fat diet. Biochemical and Biophysical Research Communications 340 1111-1118.
34. Nemoto Y, Toda K, Ono M, Fujikawa-Adachi K, Saibara T, Onishi S, Enzan H, Okada T & Shizuta Y 2000 Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice. Journal of Clinical Investigation 105 1819-1825.
35. Norris AW, Chen L, Fisher SJ, Szanto I, Ristow M, Jozsi AC, Hirshman MF, Rosen ED, Goodyear LJ, Gonzalez FJ et al. 2003 Muscle-specific PPARgdeficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. Journal of Clinical Investigation 112 608-618.
36. Novikoff PM, Roheim PS, Novikoff AB & Edelstein D 1974 Production and prevention of fatty liver in rats fed clofibrate and orotic acid diets containing sucrose. Laboratory Investigation 30 732-750.
37. Ntambi JM & Miyazaki M 2003 Recent insights into stearoyl-CoA desaturase-1. Current Opinion in Lipidology 14 255-261.
38. Ohlsson C, Hellberg N, Parini P, Vidal O, Bohlooly-Y M, Rudling M, Lindberg MK, Warner M, Angelin B & Gustafsson JA 2000 Obesity and disturbed lipoprotein profile in estrogen receptor-a-deficient male mice. Biochemical and Biophysical Research Communications 278 640-645.
39. Ohnishi T, Ogawa Y, Saibara T, Nishioka A, Kariya S, Fukumoto M, Onishi S & Yoshida S 2005 CYP17 polymorphism as a risk factor of tamoxifen-induced hepatic steatosis in breast cancer patients. Oncology Reports 13 485-489.
40. Qureshi K & Abrams GA 2007 Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World Journal of Gastroenterology 13 3540-3553.
41. Robertson KM,O'Donnell L, Jones ME, Meachem SJ, Boon WC,Fisher CR, Graves KH, McLachlan RI & Simpson ER 1999 Impairment of spermatogenesis in mice lacking a functional aromatase (cyp19) gene. PNAS 96 7986-7991.
42. Roesch DM 2006 Effects of selective estrogen receptor agonists on food intake and body weight gain in rats. Physiology & Behavior 87 39-44.
43. Ruhl CE & Everhart JE 2004 Epidemiology of nonalcoholic fatty liver. Clinics in Liver Disease 8 501-519.
44. Sader MA, McGrath KCY, Hill MD, Bradstock KF, Jimenez M, Handelsman DJ, Celermajer DS & Death AK 2005 Androgen receptor gene expression in leucocytes is hormonally regulated: implications for gender differences in disease pathogenesis. Clinical Endocrinology 62 56-63.
45. Sartor BM & Dickey RP 2005 Polycystic ovarian syndrome and the metabolic syndrome. American Journal of the Medical Sciences 330 336-342.
46. Shimano H, Horton JD, Hammer RE, Shimomura I, Brown MS & Goldstein JL 1996 Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. Journal of Clinical Investigation 98 1575-1584.
47. Shimano H, Horton JD, Shimomura I, Hammer RE, Brown MS & Goldstein JL 1997 Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. Journal of Clinical Investigation 99 846-854.
48. Shimomura I, Bashmakov Y, Ikemoto S, Horton JD, Brown MS & Goldstein JL 1999 Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. PNAS 96 13656-13661.
49. Singh J & Handelsman DJ 1996 Neonatal administration of FSH increases Sertoli cell numbers and spermatogenesis in gonadotropin-deficient (hpg) mice. Journal of Endocrinology 151 37-48.
50. Smith S 1994 The animal fatty acid synthase: one gene, one polypeptide, seven enzymes. FASEB Journal 8 1248-1259.
51. Ståhlberg N, Merino R, Hernández LH, Fernández-Pérez L, Sandelin A, Engström P, Tollet-Egnell P, Lenhard B & Flores-Morales A 2005 Exploring hepatic hormone actions using a compilation of gene expression profiles. BMC Physiology 5 8.
52. Thammacharoen S, Geary N, Lutz TA, Ogawa S & Asarian L 2009 Divergent effects of estradiol and the estrogen receptor-alpha agonist PPT on eating and activation of PVN CRH neurons in ovariectomized rats and mice. Brain Research 1268 88-96.
53. Thompson C & Lucier GW 1983 Hepatic estrogen responsiveness. Possible mechanisms for sexual dimorphism. Molecular Pharmacology 24 69-76.
54. Völzke H, Schwarz S, Baumeister SE,Wallaschofski H, Schwahn C, Grabe HJ, Kohlmann T, John U & Dören M 2007 Menopausal status and hepatic steatosis in a general female population. Gut 56 594-595.
55. Wakil SJ, Stoops JK & Joshi VC 1983 Fatty acid synthesis and its regulation. Annual Review of Biochemistry 52 537-579.
56. Waxman DJ & O'Connor C 2006 Growth hormone regulation of sexdependent liver gene expression. Molecular Endocrinology 20 2613-2629.
57. Weisinger G, Gavish M, Mazurika C & Zinder O 1999 Transcription of actin, cyclophilin and glyceraldehyde phosphate dehydrogenase genes: tissue- and treatment-specificity. Biochimica et Biophysica Acta 1446 225-232.
58. Yasutake K, Nakamuta M, Shima Y, Ohyama A, Masuda K, Haruta N, Fujino T, Aoyagi Y, Fukuizumi K, Yoshimoto T et al. 2009 Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. Scandinavian Journal of Gastroenterology 44 471-477.